Last updated on February 2018

Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Persistent Asthma
  • Age: Between 18 - 65 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Ability and willingness to provide written informed consent and to comply with the study protocol
  2. Age 18-65 years at the time of informed consent
  3. Severe asthma (BTS treatment step 4/5) despite intensive follow-up by an asthma specialist for at least 3 months
  4. Diagnosis of asthma at least 12 months prior to informed consent
  5. Baseline post bronchodilator FEV1 40% of predicted
  6. History of asthma treatment with high doses of inhaled glucocorticosteroids ( 1000 g fluticasone propionate daily or equivalent (Clenil [BDP] 2000 g, Fostair [BDP] 800 g, fluticasone furoate 192 g, budesonide dry powder 1600 g, ciclesonide 640 g), and LABA, with or without an additional controller, for at least 3 months prior to screening or previous corticosteroid optimisation (RASP workstrand 1).
  7. For patients using oral corticosteroids, adherence with oral prednisolone regimen, as demonstrated by detectable serum prednisolone and evidence of suppressed cortisol within 6 hours of reported daily dose on at least one occasion during the screening period
  8. Assessment according to the standards of the BTS UK Difficult Asthma Network or equivalent
  9. Chest X-ray or computed tomography (CT) scan obtained within 12 months prior to consent (Visit 1) or chest X-ray during the screening period (prior to Visit 2) confirming the absence of other clinically significant lung disease
  10. Documented history of bronchodilator reversibility response of 12% and 200 mL within the past 18 months, as demonstrated by any of the following:
  11. Documented airflow obstruction (FEV1/forced vital capacity [FVC] <70%), where FEV1 has varied by 12% either spontaneously or in response to oral corticosteroid therapy, or ii) PC20 (provocative concentration of methacholine producing a 20% fall in FEV1) to methacholine <8 mg/mL indicating the presence of airway hyperresponsiveness, or iii) change in FEV1 by 12% and 200 mL after acute reversibility testing with 400 g albuterol or 2.5-5 mg nebulized salbutamol

Exclusion Criteria:

  • Treatment with intravenous [IV], intramuscular [IM]) or intraarticular corticosteroids within 4 weeks prior to Visit 1 or during the screening period for any reason, including an acute exacerbation event
  • A severe asthma exacerbation requiring oral corticosteroids within 4 weeks. The patient has had an exacerbation of asthma requiring the new administration of oral steroids or an increase of at least 10 mg in their usual oral prednisolone dose within the last 4 weeks - defined from the last day of adjusted prednisolone therapy (such patients can re-screened >4 weeks from the last exacerbation)..
  • Infection that meets any of the following criteria:
  • Any infection that resulted in hospital admission for 24 hours within 4 weeks prior to Visit 1 or during screening
  • Any infection that required treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening
  • Any active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening
  • Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening
  • Antibiotics include any antimicrobial therapy used to treat bacterial, fungal, parasitic, viral, or other infections. Antibiotics prescribed for lung infection prophylaxis would also exclude the patient.
  • Active tuberculosis requiring treatment within 12 months prior to Visit 1 Patients who have completed treatment for tuberculosis at least 12 months prior to Visit 1 and have no evidence of recurrent disease are permitted.
  • Known immunodeficiency, including, but not limited to, HIV infection
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • AST, ALT, or total bilirubin elevation 2.0x the upper limit of normal (ULN) during screening
  • Clinically significant abnormality on screening electrocardiogram (ECG) or laboratory tests (haematology, serum chemistry, and urinalysis) that, in the opinion of the investigator, may pose an additional risk of bronchoscopy
  • History of clinically significant lung disease other than asthma
  • Known current malignancy or current evaluation for a potential malignancy
  • Unable to safely undergo elective flexible fiberoptic bronchoscopy because of any one of the following:
  • History of allergic reactions to local anesthetics to be used in the procedure
  • History of a clinically significant clotting abnormality, including on Screening Coagulation Panel
  • History of acute myocardial infarction, unstable angina, or other medical conditions that, in the opinion of the investigator, may make the patient unsuitable for elective bronchoscopy
  • Other clinically significant medical disease that is uncontrolled despite treatment, that is likely, in the opinion of the investigator, to impact the patient's ability to participate in the study
  • Current smoker, former smoker with smoking history of >15 pack-years A current smoker is defined as someone who has smoked at least one cigarette per day (or pipe, cigar, or marijuana) for 30 days within the 12 months prior to Visit 1. A pack-year is defined as the average number of packs of cigarettes per day times the number of years of smoking.
  • Use of a licensed or investigational monoclonal antibody including anti-IL 13, anti-IL-4/IL-13, omalizumab, anti-IL-5, or anti-IL 17, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Use of a systemic immunomodulatory or immunosuppressive therapy (other than a monoclonal antibody or corticosteroids [see separate exclusion]) within 3 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Use of other investigational therapy not described above within 4 weeks or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
  • Patients participating in a clinical trial that has not been unblinded should be assumed to have received the active drug
  • Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or during screening
  • Receipt of a live attenuated vaccine within 4 weeks prior to Visit 1 or during screening
  • Pregnant or lactating
  • History of bronchial thermoplasty

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.